Medtronic has published detailed results for the first time of a 5-year trial for deep brain stimulation therapy in treatment-resistant epilepsy. The device giant has said that it will make another run at an FDA approval for its DBS device in that indication.
The market for deep brain stimulation to treat Parkinson's is heating up. Boston Scientific said its Vercise device is performed well in clinical trials.
Medtronic has developed a first-of-its-kind implant, pairing traditional deep-brain stimulation with sensing technology, and, after performing its first procedure, the company says the device has a chance to change the standard of care for neurological disorders.
A deep brain stimulation implant used in a small pilot study helped some patients with severe anorexia gain weight and boosted their mood.
Two Medtronic deep brain stimulation device-implants, in combination with drugs, helped improve symptoms in patients with early-stage Parkinson's disease, according to a new study.
Boston Scientific ($BSX) gained a CE mark for its Vercise deep brain stimulation system as a Parkinson's disease treatment.
Deep brain stimulation seems to help improve Parkinson's disease symptoms in patients over a three-year period, according to a new VA study. That's good news for a number of device companies marketing or developing treatments in the space.
Switzerland's Aleva Neurotherapeutics is looking to make a splash with its own next-generation implants for DBS, and it has just scored 4 million Swiss francs ($4.4 million) in Series B to advance the clinical development of its products.
Cleveland-based Great Lakes NeuroTechnologies is working on deep brain stimulation systems to help Parkinson's patients.
Deep brain stimulation (DBS) is already an established treatment for patients with intractable Parkinson's or other movement disorders. Now, devicemakers like Medtronic and St. Jude are exploring the